PMID-27517151 – GHK-Cu Ameliorates LPS-Induced Acute Lung Injury
Park JR et al. "The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice," Oncotarget, 2016;7(36):58405-58417. doi:10.18632/oncotarget.11168
Quick Reference
| Property | Value |
|---|---|
| PMID | 27517151 |
| DOI | 10.18632/oncotarget.11168 |
| Year | 2016 |
| Journal | Oncotarget |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Mice with LPS-induced acute lung injury |
| Peptide(s) Studied | GHK-Cu |
Key Findings
- GHK-Cu reduced reactive oxygen species (ROS) production in lung tissue
- Increased superoxide dismutase (SOD) activity (antioxidant defense)
- Decreased TNF-α and IL-6 levels (pro-inflammatory cytokines)
- Ameliorated histological lung damage in LPS-induced acute lung injury model
- Demonstrates potent anti-inflammatory and antioxidant effects beyond skin/wound applications
Study Design
Murine acute lung injury model using lipopolysaccharide (LPS) challenge. GHK-Cu administered systemically. Outcomes: ROS levels, SOD activity, inflammatory cytokines (TNF-α, IL-6), histological lung analysis.
Limitations
- Published in Oncotarget, which has variable review quality
- Acute injury model; chronic lung disease applicability unclear
- Mouse model; human pulmonary biology differs
Clinical Relevance
Extends GHK-Cu evidence beyond skin and wound healing into pulmonary anti-inflammatory applications. The ROS/SOD/cytokine data demonstrates systemic anti-inflammatory capability relevant to the peptide's broader therapeutic profile.
Related
#research #animal-in-vivo #evidence-level-V